{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:14:51Z","timestamp":1783307691858,"version":"3.54.6"},"reference-count":310,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Molecular pharming or the technology of application of plants and plant cell culture to manufacture high-value recombinant proteins has progressed a long way over the last three decades. Whether generated in transgenic plants by stable expression or in plant virus-based transient expression systems, biopharmaceuticals have been produced to combat several human viral diseases that have impacted the world in pandemic proportions. Plants have been variously employed in expressing a host of viral antigens as well as monoclonal antibodies. Many of these biopharmaceuticals have shown great promise in animal models and several of them have performed successfully in clinical trials. The current review elaborates the strategies and successes achieved in generating plant-derived vaccines to target several virus-induced health concerns including highly communicable infectious viral diseases. Importantly, plant-made biopharmaceuticals against hepatitis B virus (HBV), hepatitis C virus (HCV), the cancer-causing virus human papillomavirus (HPV), human immunodeficiency virus (HIV), influenza virus, zika virus, and the emerging respiratory virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been discussed. The use of plant virus-derived nanoparticles (VNPs) and virus-like particles (VLPs) in generating plant-based vaccines are extensively addressed. The review closes with a critical look at the caveats of plant-based molecular pharming and future prospects towards further advancements in this technology. The use of biopharmed viral vaccines in human medicine and as part of emergency response vaccines and therapeutics in humans looks promising for the near future.<\/jats:p>","DOI":"10.3390\/vaccines9070761","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T04:32:49Z","timestamp":1625718769000},"page":"761","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?"],"prefix":"10.3390","volume":"9","author":[{"given":"Srividhya","family":"Venkataraman","sequence":"first","affiliation":[{"name":"Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hefferon","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Makhzoum","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences & Biotechnology, Botswana International University of Science & Technology, Palapye, Botswana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"Abouhaidar","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nbt1109-987","article-title":"What\u2019s fueling the biotech engine-2008","volume":"27","author":"Aggarwal","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biomaterials.2015.08.004","article-title":"Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B","volume":"70","author":"Su","year":"2015","journal-title":"Biomaterials"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/14760584.2014.913483","article-title":"Immunological aspects of using plant cells as delivery vehicles for oral vaccines","volume":"13","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14760584.2017.1232167","article-title":"Plant-based vaccines against respiratory diseases: Current status and future prospects","volume":"16","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11103-014-0279-5","article-title":"Current status of viral expression systems in plants and perspectives for oral vaccines development","volume":"87","year":"2015","journal-title":"Plant Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-62703-995-6_5","article-title":"Engineering chloroplasts for high-level foreign protein expression","volume":"1132","author":"Bock","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-arplant-050213-040212","article-title":"Engineering plastid genomes: Methods, tools, and applications in basic research and biotechnology","volume":"66","author":"Bock","year":"2015","journal-title":"Annu. Rev. Plant Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/jmbi.2001.4960","article-title":"Transgenic plastids in basic research and plant biotechnology","volume":"312","author":"Bock","year":"2001","journal-title":"J. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/biot.200600145","article-title":"Production of biopharmaceuticals and vaccines in plants via the chloroplast genome","volume":"1","author":"Daniell","year":"2006","journal-title":"Biotechnol. J."},{"key":"ref_10","unstructured":"Mendoza, S.R. (2014). Principles of plant-based vaccines. Genetically Engineered Plants as a Source of Vaccines against Wide Spread Diseases\u2014An Integrated View, Springer Science + Business Media."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1586\/14760584.2014.953064","article-title":"Transgenic plants: A 5-year update on oral antipathogen vaccine development","volume":"13","author":"Rosas","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_12","unstructured":"Mendoza, S.R. (2014). Seed-based expression strategies. Genetically Engineered Plants as a Source of Vaccines against Wide Spread Diseases\u2014An Integrated View, Springer Science + Business Media."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Joung, Y.H., Park, S.H., Moon, K.-B., Jeon, J.-H., Cho, H.-S., and Kim, H.-S. (2016). The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101715"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.1038\/s41598-017-08247-9","article-title":"Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3389\/fimmu.2020.02074","article-title":"Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus","volume":"11","author":"Mobini","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.antiviral.2017.06.017","article-title":"A novel chimeric Hepatitis B virus S\/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein","volume":"144","author":"Dobrica","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3748\/wjg.v13.i1.65","article-title":"Hepatitis B virus morphogenesis","volume":"13","author":"Bruss","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/jvi.52.2.396-402.1984","article-title":"Large surface proteins of hepatitis B virus containing the pre-s sequence","volume":"52","author":"Heermann","year":"1984","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/0140-6736(90)91138-Z","article-title":"Modern vaccines. Hepatitis","volume":"335","author":"Eddleston","year":"1990","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nbt.2009.01.001","article-title":"Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: Implications for the design of new vaccine strategies","volume":"25","author":"Patient","year":"2009","journal-title":"New Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000150244","article-title":"Atopological Model for Hepatitis B Surface Antigen","volume":"33","author":"Stirk","year":"1992","journal-title":"Intervirology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","article-title":"Human hepatitis B vaccine from recombinant yeast","volume":"307","author":"McAleer","year":"1984","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2015.04.080","article-title":"Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses","volume":"33","author":"Hayden","year":"2015","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12033-014-9837-y","article-title":"Carrot Cells: A Pioneering Platform for Biopharmaceuticals Production","volume":"57","year":"2015","journal-title":"Mol. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1467-7652.2007.00316.x","article-title":"High-yield rapid production of hepatitis B surface antigen in plant leaf by a viral expression system","volume":"5","author":"Huang","year":"2008","journal-title":"Plant Biotechnol. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12985-014-0205-0","article-title":"Plant-based vaccines against viruses","volume":"11","author":"Rybicki","year":"2014","journal-title":"Virol. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.vaccine.2004.11.017","article-title":"Virus-like particle expression and assembly in plants: Hepatitis B and Norwalk viruses","volume":"23","author":"Huang","year":"2005","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.vaccine.2005.12.024","article-title":"Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice","volume":"24","author":"Huang","year":"2006","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1016\/j.vaccine.2018.07.072","article-title":"Oral administration of a chimeric Hepatitis B Virus S\/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice","volume":"36","author":"Dobrica","year":"2018","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zahmanova, G., Mazalovska, M., Takova, K., Toneva, V., Minkov, I., Peyret, H., and Lomonossoff, G. (2021). Efficient Production of Chimeric Hepatitis B Virus-Like Particles Bearing an Epitope of Hepatitis E Virus Capsid by Transient Expression in Nicotiana Benthamiana. Life, 11.","DOI":"10.3390\/life11010064"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/13880209.2015.1048371","article-title":"Co-expression of hepatitis C virus polytope\u2013HBsAg and p19-silencing suppressor protein in tobacco leaves","volume":"54","author":"Mohammadzadeh","year":"2016","journal-title":"Pharm. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1503\/cmaj.140151","article-title":"Sofosbuvir for the treatment of hepatitis C virus infection","volume":"187","author":"Rolland","year":"2015","journal-title":"CMAJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.micpath.2013.02.005","article-title":"Hepatitis C virus vaccines\u2014Progress and perspectives","volume":"58","author":"Fauvelle","year":"2013","journal-title":"Microb. Pathog."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bpg.2012.09.006","article-title":"Virology of hepatitis C virus infection","volume":"26","author":"Chevaliez","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_36","first-page":"1","article-title":"The origin of hepatitis C virus","volume":"369","author":"Simmonds","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s007050170142","article-title":"Down-regulation of translation driven by hepatitis C virus internal ribosomal entry site by the 3\u2032 untranslated region of RNA","volume":"146","author":"Murakami","year":"2001","journal-title":"Arch. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12047","DOI":"10.1128\/JVI.75.24.12047-12057.2001","article-title":"Sequences in the 5\u2032 nontranslated region of hepatitis C virus required for RNA replication","volume":"75","author":"Friebe","year":"2001","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Deforges","year":"2002","journal-title":"J. Virol."},{"key":"ref_40","first-page":"199","article-title":"Virion Assembly and Release","volume":"369","author":"Lindenbach","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_41","first-page":"87","article-title":"Hepatitis C virus entry","volume":"369","author":"Zeisel","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on Clathrin-mediated endocytosis","volume":"80","author":"Blanchard","year":"2006","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0034-1371006","article-title":"Targets for antiviral therapy of hepatitis C","volume":"34","author":"Rupp","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_44","first-page":"113","article-title":"Hepatitis C virus proteins: From structure to function","volume":"369","author":"Moradpour","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbiotec.2009.12.001","article-title":"A hepatitis C virus core polypeptide expressed in chloroplasts detects anti-core antibodies in infected human sera","volume":"145","author":"Madesis","year":"2010","journal-title":"J. Biotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e20524","DOI":"10.5812\/hepatmon.20524","article-title":"Enhanced-Transient Expression of Hepatitis C Virus Core Protein in Nicotiana tabacum, a Protein with Potential Clinical Applications","volume":"14","author":"Mohammadzadeh","year":"2014","journal-title":"Hepat. Mon."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/apm.13074","article-title":"Canola oilseed- and Escherichia coli- derived hepatitis C virus (HCV) core proteins adjuvanted with oil bodies, induced robust Th1-oriented immune responses in immunized mice","volume":"128","author":"Mohammadzadeh","year":"2020","journal-title":"APMIS"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2007.01.011","article-title":"Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization","volume":"363","author":"Denis","year":"2007","journal-title":"Virology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/pbi.12743","article-title":"Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination","volume":"15","author":"Clarke","year":"2017","journal-title":"Plant Biotech. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s007050070008","article-title":"Development of a plant-derived subunit vaccine candidate against hepatitis C virus","volume":"145","author":"Nemchinov","year":"2000","journal-title":"Arch. Virol."},{"key":"ref_51","first-page":"7","article-title":"Expression of chimeric HCV peptide in transgenic tobacco plants infected with recombinant alfalfa mosaic virus for development of a plant-derived vaccine against HCV African J","volume":"3","author":"Attar","year":"2004","journal-title":"Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00705-003-0190-x","article-title":"Cucumber mosaic virus as carrier of a hepatitis C virus-derived epitope","volume":"149","author":"Natilla","year":"2003","journal-title":"Arch. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10875-005-2820-4","article-title":"Immunogenic Properties of a Chimeric Plant Virus Expressing a Hepatitis C Virus (HCV)-Derived Epitope: New Prospects for an HCV Vaccine","volume":"25","author":"Piazzolla","year":"2005","journal-title":"J. Clin. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00705-006-0916-7","article-title":"Cucumber mosaic virus as a presentation system for a double hepatitis C virus-derived epitope","volume":"152","author":"Nuzzaci","year":"2007","journal-title":"Arch. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jviromet.2010.01.021","article-title":"In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine","volume":"165","author":"Nuzzaci","year":"2010","journal-title":"J. Virol. Meth."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/14760584.2015.989988","article-title":"Advances and challenges in the development and production of effective plant-based influenza vaccines","volume":"14","author":"Yusibov","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_57","unstructured":"Knipe, D.M., Howley, P.M., and Griffin, D.E. (2001). Orthomyxoviridae: The Viruses and Their Replication. Fields Virology, Lippincott Williams & Wilkins. [4th ed.]."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature04378","article-title":"Architecture of ribonucleoprotein complexes in influenza A virus particles","volume":"439","author":"Noda","year":"2006","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbamem.2010.04.015","article-title":"Influenza M2 proton channels","volume":"1808","author":"Pielak","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11538","DOI":"10.1128\/JVI.74.24.11538-11547.2000","article-title":"Influenza virus matrix protein is the major driving force in virus budding","volume":"74","author":"Albo","year":"2000","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2009.05.010","article-title":"Influenza virus morphogenesis and budding","volume":"143","author":"Nayak","year":"2009","journal-title":"Virus Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1749-6632.2010.05829.x","article-title":"Structural basis of influenza virus neutralization","volume":"1217","author":"Han","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","article-title":"Influenza hemagglutinin and neuraminidase membrane glycoproteins","volume":"285","author":"Gamblin","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ajem.2009.04.003","article-title":"Building an effective ED influenza vaccine program","volume":"27","author":"Greenberg","year":"2009","journal-title":"Am. J. Emerg. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)62003-1","article-title":"Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: A multicentre, double-blind, randomised, placebo-controlled trial","volume":"375","author":"Liang","year":"2010","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(09)62026-2","article-title":"Immune response after a single vaccination against 2009 influenza A H1N1 in USA: A preliminary report of two randomised controlled phase 2 trials","volume":"375","author":"Plennevaux","year":"2010","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/592172","article-title":"Safety and immunogenicity of an inactivated influenza A\/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase I-II randomized clinical trial","volume":"198","author":"Keitel","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1016\/j.vaccine.2008.05.077","article-title":"Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/B978-0-12-385034-8.00003-X","article-title":"Influenza vaccines: The good, the bad, and the eggs","volume":"77","author":"Jones","year":"2010","journal-title":"Adv. Virus Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.1016\/j.vaccine.2011.08.008","article-title":"A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups","volume":"29","author":"Michiels","year":"2011","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2174\/1381612824666180309125344","article-title":"Plant-produced Recombinant Influenza A Vaccines Based on the M2e Peptide","volume":"24","author":"Mardanova","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_73","unstructured":"Pellerin, C. (2010). DARPA Effort Speeds Biothreat Response. American Forces Press Service, U.S. Department of Defense."},{"key":"ref_74","unstructured":"(2012, July 25). DARPA Makes 10 Million Strides in the Race to Contain a Hypothetical Pandemic. Available online: http:\/\/www.darpa.mil\/NewsEvents\/Releases\/2012\/07\/25.aspx."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Landry, N., Ward, B.J., Trepanier, S., Montomoli, E., Dargis, M., Lapini, G., and Vezina, L.P. (2010). Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015559"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-017-0043-3","article-title":"Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial","volume":"3","author":"Pillet","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1016\/j.vaccine.2015.09.065","article-title":"Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets","volume":"33","author":"Pillet","year":"2015","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clim.2016.03.008","article-title":"A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults","volume":"168","author":"Pillet","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Pillet, S., Couillard, J., Tr\u00e9panier, S., Poulin, J.F., Yassine-Diab, B., Guy, B., Ward, B.J., and Landry, N. (2019). Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and \u226550 years old adults. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216533"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(20)32014-6","article-title":"Efficacy, immuno-genicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18\u201364 years) and older adults (\u226565 years): Two multicentre, randomised phase 3 trials","volume":"396","author":"Ward","year":"2020","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0140-6736(20)32010-9","article-title":"First human efficacy study of a plant derived influenza vaccine","volume":"396","author":"Tregoning","year":"2020","journal-title":"Lancet"},{"key":"ref_82","unstructured":"(2018, June 01). Medicago. Available online: https:\/\/www.nature.com\/articles\/d43747-020-00537-y."},{"key":"ref_83","unstructured":"(2021, May 26). Medicago\u2019s Plant-Based COVID-19 Vaccine Shows Positive Phase 2 Results. Available online: https:\/\/www.isaaa.org\/kc\/cropbiotechupdate\/article\/default.asp?ID=18790."},{"key":"ref_84","unstructured":"Mapp Biopharmaceutical, and Gantz, S. Emergent BioSolutions among three under consideration for Ebola drug manufacturing. Baltim. Bus. J., Available online: https:\/\/www.bizjournals.com\/baltimore\/news\/2014\/10\/20\/emergent-biosolutions-among-three-under.html."},{"key":"ref_85","unstructured":"(2013, June 20). Medicago successfully produces plant-based Rotavirus VLP vaccine candidate. Available online: https:\/\/www.prnewswire.com\/news-releases\/medicago-successfully-produces-plant-based-rotavirus-vlp-vaccine-candidate-212290651.html."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/315653","article-title":"Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes","volume":"182","author":"Tacket","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/S0264-410X(02)00260-8","article-title":"Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine","volume":"20","author":"Yusibov","year":"2002","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1096\/fasebj.13.13.1796","article-title":"A plant-derived edible vaccine against hepatitis B virus","volume":"13","author":"Kapusta","year":"1999","journal-title":"FASEB J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1073\/pnas.0409899102","article-title":"Immunogenicity in humans of an edible vaccine for hepatitis B","volume":"102","author":"Thanavala","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.4049\/jimmunol.0901480","article-title":"A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity","volume":"183","author":"Nochi","year":"2009","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/pbi.12071","article-title":"Induction of toxin-specific neutralizing immunity by molecularly uniform rice-based oral cholera toxin B subunit vaccine without plant-associated sugar modification","volume":"11","author":"Yuki","year":"2013","journal-title":"Plant Biotechnol. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12033-019-00222-1","article-title":"Edible Vaccines: Promises and Challenges","volume":"62","author":"Kurup","year":"2020","journal-title":"Mol. Biotechnol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4161\/hv.27567","article-title":"Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge","volume":"10","author":"Mallajosyula","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2018.02.106","article-title":"Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy","volume":"36","author":"Lindsay","year":"2018","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Pushko, P., and Tretyakova, I. (2020). Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development. Viruses, 12.","DOI":"10.3390\/v12050518"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1016\/j.vaccine.2018.10.099","article-title":"Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin","volume":"36","author":"Won","year":"2018","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mardanova, E.S., Kotlyarov, R.Y., Kuprianov, V.V., Stepanova, L.A., Tsybalova, L.M., Lomonosoff, G.P., and Ravin, N.V. (2015). Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors. BMC Biotechnol., 15.","DOI":"10.1186\/s12896-015-0164-6"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/vim.2015.0050","article-title":"Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB\/C Mice","volume":"29","author":"Ameghi","year":"2016","journal-title":"Viral Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2017.06.001","article-title":"Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge","volume":"509","author":"Deng","year":"2017","journal-title":"Virology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-018-0433-5","article-title":"Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes","volume":"25","author":"Stepanova","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"85","DOI":"10.32607\/20758251-2018-10-1-85-94","article-title":"Influence of the Linking Order of Fragments of HA2 and M2e of the influenza A Virus to Flagellin on the Properties of Recombinant Proteins","volume":"10","author":"Stepanova","year":"2018","journal-title":"Acta Nat."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1016\/j.vaccine.2014.08.079","article-title":"Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines","volume":"32","author":"Ward","year":"2014","journal-title":"Vaccine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1016\/j.vaccine.2017.07.012","article-title":"Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes\/macrophages","volume":"35","author":"Makarkov","year":"2017","journal-title":"Vaccine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1016\/j.vaccine.2015.10.123","article-title":"Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine","volume":"33","author":"Carignan","year":"2015","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12951-017-0289-y","article-title":"A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling","volume":"15","author":"Carignan","year":"2017","journal-title":"J. Nanobiotechnology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1016\/j.nano.2018.08.010","article-title":"The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses","volume":"14","author":"Bolduc","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.vaccine.2008.04.052","article-title":"Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform","volume":"26","author":"Denis","year":"2008","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-3155-11-10","article-title":"Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP","volume":"11","author":"Babin","year":"2013","journal-title":"J. Nanobiotechnol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lalibert\u00e9-Gagn\u00e9, M.-E., Bolduc, M., Th\u00e9rien, A., Garneau, C., Casault, P., Savard, P., Estaquier, J., and Leclerc, D. (2019). Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform. Vaccines, 7.","DOI":"10.3390\/vaccines7020049"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1128\/JVI.01720-06","article-title":"Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells","volume":"81","author":"Leclerc","year":"2007","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Zahmanova, G.G., Mazalovska, M., Takova, K.H., Toneva, V.T., Minkov, I.N., Mardanova, E.S., Ravin, N.V., and Lomonossoff, G.P. (2019). Rapid High-Yield Transient Expression of Swine Hepatitis E ORF2 Capsid Proteins in Nicotiana benthamiana Plants and Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope. Plants, 9.","DOI":"10.3390\/plants9010029"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Blokhina, E.A., Mardanova, E.S., Stepanova, L.A., M Tsybalova, L.M., and Ravin, N.V. (2020). Plant-Produced Recombinant Influenza A Virus Candidate Vaccine Based on Flagellin Linked to Conservative Fragments of M2 Protein and Hemagglutintin. Plants, 9.","DOI":"10.3390\/plants9020162"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12951-017-0305-2","article-title":"Nanodiamond enhances immune responses in mice against recombinant HA\/H7N9 protein","volume":"15","author":"Pham","year":"2017","journal-title":"J. Nanobiotechnol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/pbi.13219","article-title":"Efficacy of a plant-produced virus-like particle vaccine in chickens challenged with Influenza A H6N2 virus","volume":"18","author":"Smith","year":"2020","journal-title":"Plant Biotechnol. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"key":"ref_118","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/rmv.1824","article-title":"Recent progress in vaccination against human papillomavirus-mediated cervical cancer","volume":"25","author":"McKee","year":"2015","journal-title":"Rev. Med. Virol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1128\/JVI.77.17.9211-9220.2003","article-title":"Production of human papillomavirus type 16 virus-like particles in transgenic plants","volume":"77","author":"Biemelt","year":"2003","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/189895a0","article-title":"Morphological characterization of the virus of the human common wart (verruca vulgaris)","volume":"189","author":"Williams","year":"1961","journal-title":"Nature"},{"key":"ref_122","unstructured":"Bernard, F.N., Diane, G.E., Peter, H.M., and David, K.M. (2001). Fields Virology, Lippincott Williams & Wilkins. [2nd ed.]."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/sj.onc.1206554","article-title":"Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation","volume":"22","author":"Fehrmann","year":"2003","journal-title":"Oncogene"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/viro.1997.8591","article-title":"Chimeric papillomavirus like particles","volume":"234","author":"Braspenning","year":"1997","journal-title":"Virology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/hv.18568","article-title":"Plant-derived vaccines: An approach for affordable vaccines against cervical cancer","volume":"8","author":"Waheed","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1467-7652.2010.00507.x","article-title":"Plant made vaccines for humans and animals","volume":"8","author":"Rybicki","year":"2010","journal-title":"Plant Biotechnol. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pbi.2004.01.007","article-title":"Plant-based production of biopharmaceuticals","volume":"7","author":"Fischer","year":"2004","journal-title":"Curr. Opin. Plant Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fpls.2019.00779","article-title":"Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity","volume":"10","author":"Chabeda","year":"2019","journal-title":"Front. Plant Sci."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Naupu, P.N., van Zyl, A.R., Rybicki, E.P., and Hitzeroth, I.I. (2020). Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs). Vaccine, 8.","DOI":"10.3390\/vaccines8040740"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Latif, S., Gottschamel, J., Syed, T., Younus, I., Gull, K., Sameeullah, M., Batool, N., L\u00f6ssl, A.G., Mariz, F., and M\u00fcller, M. (2021). Inducible expression of human papillomavirus-16 L1 capsomeres in the plastomes of Nicotiana tabacum: Transplastomic plants develop normal flowers and pollen. Biotechnol. Appl. Biochem.","DOI":"10.1002\/bab.2136"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1134\/S1607672919010150","article-title":"The New Plant Expression System for the Development of Vaccines against Papillomaviruses","volume":"484","author":"Salyaev","year":"2019","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fpls.2019.00452","article-title":"Bioproduction of a Therapeutic Vaccine Against Human Papillomavirus in Tomato Hairy Root Cultures","volume":"10","author":"Massa","year":"2019","journal-title":"Front. Plant Sci."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Yazdani, R., Shams-Bakhsh, M., Hassani-Mehraban, A., Arab, S.S., Thelen, N., Thiry, M., Crommen, J., Fillet, M., Jacobs, N., and Brans, A. (2019). Production and characterization of virus like particles of grapevine fanleaf virus presenting L2 epitope of human papillomavirus minor capsid protein. BMC Biotechnol., 19.","DOI":"10.1186\/s12896-019-0566-y"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.vaccine.2018.11.021","article-title":"Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen","volume":"37","author":"Diamos","year":"2019","journal-title":"Vaccine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.copbio.2020.01.004","article-title":"Plant-made HIV vaccines and potential candidates","volume":"61","author":"Moustafa","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jim.2014.11.006","article-title":"Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development","volume":"416","author":"Stephenson","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e34420","DOI":"10.7554\/eLife.34420","article-title":"Mapping mutational effects along the evolutionary landscape of HIV envelope","volume":"7","author":"Haddox","year":"2018","journal-title":"eLife"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1074\/jbc.RA118.005006","article-title":"Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4- binding site neutralizing antibodies","volume":"293","author":"Rathore","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11248-009-9244-5","article-title":"Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study","volume":"18","author":"Marusic","year":"2009","journal-title":"Transgenic Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/pbi.13090","article-title":"A novel anti-HIV-1 bispecific bNAb-lectin fusion protein engineered in a plant-based transient expression system","volume":"17","author":"Dent","year":"2019","journal-title":"Plant Biotechnol. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/pbi.12416","article-title":"Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants","volume":"13","author":"Ma","year":"2015","journal-title":"Plant Biotechnol. J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11240-012-0252-4","article-title":"Production of an antigenic C4 (V3) 6 multiepitopic HIV protein in bacterial and plant systems","volume":"113","author":"Korban","year":"2013","journal-title":"Plant Cell Tissue Organ. Cult."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11240-013-0387-y","article-title":"Chloroplast expression of an HIV envelop-derived multiepitope protein: Towards a multivalent plant-based vaccine","volume":"116","year":"2014","journal-title":"Plant Cell Tissue Organ. Cult."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coviro.2017.07.019","article-title":"Using transgenic plants and modified plant viruses for the development of treatments for human diseases","volume":"26","author":"Loh","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00299-014-1720-6","article-title":"An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice","volume":"34","author":"Parsons","year":"2015","journal-title":"Plant Cell Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.chroma.2018.08.014","article-title":"A linear epitope coupled to DsRed provides an affinity ligand for the capture of monoclonal antibodies","volume":"1571","author":"Ruhl","year":"2018","journal-title":"J. Chromatogr. A"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s12033-015-9856-3","article-title":"A plant-derived derived multi-HIV antigen induces broad immune responses in orally immunized mice","volume":"57","author":"Korban","year":"2015","journal-title":"Mol. Biotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"E7854","DOI":"10.1073\/pnas.1806022115","article-title":"Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm","volume":"115","author":"Vamvaka","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Fuqua, J.L., Wanga, V., and Palmer, K.E. (2015). Improving the large scale purification of the HIV microbicide, griffithsin. BMC Biotechnol., 15.","DOI":"10.1186\/s12896-015-0120-5"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fbioe.2018.00102","article-title":"Technoeconomic modeling of plant-based Griffithsin manufacturing","volume":"6","author":"Alam","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1080\/19420862.2016.1227901","article-title":"Techno-economic analysis of a transient plant-based platform for monoclonal antibody production","volume":"8","author":"Nandi","year":"2016","journal-title":"MAbs"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fbioe.2018.00206","article-title":"A combined ultrafiltration\/diafiltration step facilitates the purification of cyanovirin-N from transgenic tobacco extracts","volume":"6","author":"Opdensteinen","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1074\/jbc.M109.034926","article-title":"A lectin isolated from bananas is a potent inhibitor of HIV replication","volume":"285","author":"Swanson","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.str.2017.03.015","article-title":"The tetrameric plant lectin BanLec neutralizes HIV through bidentate binding to specific viral glycans","volume":"25","author":"Hopper","year":"2017","journal-title":"Structure"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3389\/fpls.2019.01378","article-title":"Production and immunogenicity of soluble plant-produced HIV-1 subtype C envelope gp140 immunogens","volume":"10","author":"Margolin","year":"2019","journal-title":"Front. Plant Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11103-015-0425-8","article-title":"Efficient expression of nuclear transgenes in the green alga Chlamydomonas: Synthesis of an HIV antigen and development of a new selectable marker","volume":"90","author":"Barahimipour","year":"2016","journal-title":"Plant Mol. Biol."},{"key":"ref_161","unstructured":"D\u2019Aoust, M.A., Couture, M.M., Lavoie, P.O., and Vezina, L.P. (2012). Virus Like Particle Production in Plants. (WO2012083445 (A1)), Patent number."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1128\/JVI.00542-07","article-title":"Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles","volume":"81","author":"Wang","year":"2007","journal-title":"J. Virol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/pbi.12058","article-title":"Biological and biochemical characterization of HIV-1 Gag\/dgp41 virus-like particles expressed in Nicotiana benthamiana","volume":"11","author":"Kessans","year":"2013","journal-title":"Plant Biotechnol. J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00425-009-0898-2","article-title":"High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts","volume":"229","author":"Scotti","year":"2009","journal-title":"Planta"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1006\/viro.1994.1417","article-title":"Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides","volume":"202","author":"Porta","year":"1994","journal-title":"Virology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/aid.1995.11.327","article-title":"Human immunodeficiency virus type 1-neutralizing anti-bodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus","volume":"11","author":"McLain","year":"1995","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0264-410X(95)00229-T","article-title":"Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus","volume":"14","author":"McLain","year":"1996","journal-title":"Vaccine"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1099\/0022-1317-79-11-2709","article-title":"The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731\u2013752) is uniquely directed against a conformational epitope","volume":"79","author":"Buratti","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1385\/MB:20:2:131","article-title":"Production of HIV-1 p24 protein in transgenic tobacco plants","volume":"20","author":"Zhang","year":"2002","journal-title":"Mol. Biotechnol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.vaccine.2004.11.021","article-title":"Plant based HIV-1 vaccine candidate: Tat protein produced in spinach","volume":"23","author":"Karasev","year":"2005","journal-title":"Vaccine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14712598.2020.1752177","article-title":"Will plant-made biopharmaceuticals play a role in the fight against COVID-19?","volume":"20","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"26","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e00710-18","DOI":"10.1128\/JVI.00710-18","article-title":"Combination attenuation offers strategy for live attenuated coronavirus vaccines","volume":"92","author":"Menachery","year":"2018","journal-title":"J. Virol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2019.05.001","article-title":"Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease","volume":"168","author":"Kotomina","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1016\/j.vaccine.2007.04.065","article-title":"Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques","volume":"25","author":"Kobinger","year":"2007","journal-title":"Vaccine"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus\u2013Infected Pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/jmv.25727","article-title":"Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1038\/s41467-019-10661-8","article-title":"Quantification of epitope abundance reveals the effect of direct and cross-presentation on influenza CTL responses","volume":"10","author":"Wu","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Armbruster, N., Jasny, E., and Petsch, B. (2019). Advances in RNA vaccines for preventive indications: A case study of a vaccine against rabies. Vaccines, 7.","DOI":"10.3390\/vaccines7040132"},{"key":"ref_183","unstructured":"(2020, March 25). CureVac Focuses on the Development of mRNA-Based Coronavirus Vaccine to Protect People Worldwide. Available online: https:\/\/www.curevac.com\/news\/curevac-focuses-on-the-development-of-mrna-basedcoronavirus-vaccine-to-protect-people-worldwide."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Mahmood, N., Nasir, S.B., and Hefferon, K. (2021). Plant-Based Drugs and Vaccines for COVID-19. Vaccines, 9.","DOI":"10.3390\/vaccines9010015"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Gralinski, L.E., and Menachery, V.D. (2020). Return of the coronavirus: 2019-nCoV. Viruses, 12.","DOI":"10.3390\/v12020135"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS","volume":"9","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014A target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg. Infect. Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1128\/JVI.03566-14","article-title":"Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates","volume":"89","author":"Fett","year":"2015","journal-title":"J. Virol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1292\/jvms.18-0702","article-title":"Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route","volume":"81","author":"Takano","year":"2019","journal-title":"J. Vet. Med. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.tplants.2020.04.009","article-title":"Potential Applications of Plant Biotechnology against SARS-CoV-2","volume":"25","author":"Capell","year":"2020","journal-title":"Trends Plant Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An MRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Mulligan, M.J., Lyke, K.E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.P., Neuzil, K., Raabe, V., Bailey, R., and Swanson, K.A. (2020). Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. Nature.","DOI":"10.1101\/2020.06.30.20142570"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind, Randomised Controlled Trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_196","unstructured":"(2021, July 01). Novavax.com. Clinical Stage Pipeline\u2013Novavax\u2212Creating Tomorrow\u2019s Vaccines Today. Available online: https:\/\/novavax.com\/ourpipeline#nvx-cov2373."},{"key":"ref_197","unstructured":"Gretler, C. (2020, December 24). Tobacco-Based Coronavirus Vaccine Poised for Human Tests Bloomberg. Available online: https:\/\/www.bloomberg.com\/news\/articles\/2020-05-15\/cigarette-maker-s-coronavirus-vaccine-poised-for-human-tests."},{"key":"ref_198","unstructured":"Palca, J. (2020, December 20). Tobacco Plants Contribute Key Ingredient For COVID-19 Vaccine. Available online: https:\/\/www.npr.org\/sections\/health-shots\/2020\/10\/15\/923210562\/tobacco-plants-contribute-key-ingredient-for-covid-19-vaccine#:~{}:text=Historically%2C%20tobacco%20plants%20are%20responsible,be%20used%20in%20a%20vaccine."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1074\/mcp.M300048-MCP200","article-title":"Mass spectrometric characterization of proteins from the SARS virus: A preliminary report","volume":"2","author":"Krokhin","year":"2003","journal-title":"Mol. Cell. Proteom."},{"key":"ref_200","unstructured":"Mullan, K. (2020, December 24). Tobacco Giant BAT Says It Could be Making 1 to 3 Million COVID-19 Vaccines a Week by June. Available online: https:\/\/www.derryjournal.com\/news\/people\/tobacco-giant-bat-says-it-could-be-making-1-3-million-covid-19-vaccines-week-june-2526933."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.biotechadv.2015.03.012","article-title":"Transient plant transformation mediated by Agrobacterium tumefaciens: Principles, methods and applications","volume":"33","author":"Krenek","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Ward, B.J., Gobeil, P., S\u00e9guin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D\u2019Aoust, M.-A., Dhaliwall, J., and Finkle, C. (2020). Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants. MedRxiv.","DOI":"10.1101\/2020.11.04.20226282"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Rosales-Mendoza, S., M\u00e1rquez-Escobar, V.A., Gonz\u00e1lez-Ortega, O., Nieto-G\u00f3mez, R., and Ar\u00e9valo-Villalobos, J.I. (2020). What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?. Vaccines, 8.","DOI":"10.3390\/vaccines8020183"},{"key":"ref_204","unstructured":"(2020, October 24). Phillip Morris International. Available online: https:\/\/www.pmi.com\/media-center\/news\/pmi-announces-medicago-to-supply-up-to-76-million-doses-of-its-plant-derived-covid-19-vaccine-candidate."},{"key":"ref_205","unstructured":"Makay, C. (2020, December 24). Algae Tasked with Making COVID-19 Kits. Available online: https:\/\/phys.org\/news\/2020-04-algae-taskedcovid-kits.html."},{"key":"ref_206","unstructured":"(2020, September 16). Available online: https:\/\/www.biospace.com\/article\/ibio-s-fastpharming-platform-produces-decoy-therapeutic-to-bind-to-sars-cov-2\/."},{"key":"ref_207","unstructured":"Nogrady, B. (2020, December 24). How SARS-CoV-2 TestsWork and What\u2019s Next in COVID-19 Diagnostics. The Scientist 2020. Available online: https:\/\/www.the-scientist.com\/news-opinion\/how-sars-cov-2-tests-work-and-whats-next-in-covid-19-diagnostics-67210."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"e1905740","DOI":"10.1002\/adma.201905740","article-title":"Built-In Active Microneedle Patch with Enhanced Autonomous Drug Delivery","volume":"32","author":"Soto","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Zhang, W., Bailey-Elkin, B.A., Knaap, R.C.M., Khare, B., Dalebout, T.J., Johnson, G.G., Van Kasteren, P.B., McLeish, N.J., Gu, J., and He, W. (2017). Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006372"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Clemente, V., D\u2019Arcy, P., and Bazzaro, M. (2020). Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103492"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/vaccines2030642","article-title":"DNA Virus Vectors for Vaccine Production in Plants: Spotlight on Geminiviruses","volume":"2","author":"Hefferon","year":"2014","journal-title":"Vaccines"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-74904-1","article-title":"Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana","volume":"10","author":"Rattanapisit","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.vaccine.2020.02.089","article-title":"Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity","volume":"38","author":"Diamos","year":"2020","journal-title":"Vaccine"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Wilder-Smith, A., Vannice, K., Durbin, A., Hombach, J., Thomas, S.J., Thevarjan, I., and Simmons, C.P. (2018). Zika vaccines and therapeutics: Landscape analysis and challenges ahead. BMC Med., 16.","DOI":"10.1186\/s12916-018-1067-x"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/14760584.2017.1345309","article-title":"An update on Zika vaccine developments","volume":"16","author":"Durbin","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_217","unstructured":"(NIAID) NI of A and, ID (2019, May 03). VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents (DNA) n.d. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03110770."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro.2015.28","article-title":"ZIKA virus circulates in new regions","volume":"14","author":"Attar","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 Syndrome outbreak associated with Zika virus infection in French Polynesia: A case control study","volume":"387","author":"Blake","year":"2016","journal-title":"Lancet"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1128\/JVI.00252-16","article-title":"Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere","volume":"90","author":"Lazear","year":"2016","journal-title":"J. Virol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1126\/science.aaf5316","article-title":"The 3.8 \u00c5 resolution cryo-EM structure of Zika virus","volume":"352","author":"Sirohi","year":"2016","journal-title":"Science"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imr.12367","article-title":"Fc receptors in antibody-dependent enhancement of viral infections","volume":"268","author":"Taylor","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1080\/21645515.2015.1116655","article-title":"Recombinant immune complexes as versatile and potent vaccines","volume":"12","author":"Mason","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.15252\/emmm.201606593","article-title":"Immunoregulatory functions of immune complexes in vaccine and therapy","volume":"8","author":"Wen","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.4049\/jimmunol.1602169","article-title":"C1qdependent dendritic cell cross-presentation of in vivo-formed antigen\u2013antibody complexes","volume":"198","author":"Ho","year":"2017","journal-title":"J. Immunol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4049\/jimmunol.1700911","article-title":"Formation of immune complexes with a tetanus-derived B Cell epitope boosts human T cell responses to covalently linked peptides in an ex vivo blood loop system","volume":"201","author":"Fletcher","year":"2018","journal-title":"J. Immunol."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Cabral-Miranda, G., Lim, S.M., Mohsen, M.O., Pobelov, I.V., Roesti, E.S., Heath, M.D., Skinner, M.A., Kramer, M.F., Martina, B.E.E., and Bachmann, M.F. (2019). Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines, 7.","DOI":"10.3390\/vaccines7030072"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fbioe.2019.00472","article-title":"High Level Production of Monoclonal Antibodies Using an Optimized Plant Expression System","volume":"7","author":"Diamos","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1016\/j.vaccine.2018.08.033","article-title":"Safety and immunogenicity of a plant produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A phase 1 dose-escalation study in healthy adults","volume":"36","author":"Chichester","year":"2018","journal-title":"Vaccine"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0168-9452(01)00555-6","article-title":"Expression of Plasmodium falciparum C-terminal region of merozoite surface protein (PfMSP119), a potential malaria vaccine candidate, in tobacco","volume":"162","author":"Ghosh","year":"2002","journal-title":"Plant Sci."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1186\/1475-2875-7-S1-S10","article-title":"Malaria vaccines and their potential role in the elimination of malaria","volume":"7","author":"Targett","year":"2008","journal-title":"Malar. J."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.vaccine.2006.09.074","article-title":"A review of human vaccine research and development: Malaria","volume":"25","author":"Girard","year":"2007","journal-title":"Vaccine"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.4049\/jimmunol.172.10.6167","article-title":"Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody mediated inhibition of parasite growth in vitro","volume":"172","author":"Pan","year":"2004","journal-title":"J. Immunol."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Hamid, M.M., Remarque, E.J., van Duivenvoorde, L.M., van der Werff, N., Walraven, V., Faber, B.W., Kocken, C.H.M., and Thomas, A.W. (2011). Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT\u2122 protects against blood-stage challenge in Rhesus macaques. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020547"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpara.2007.06.005","article-title":"Immunogenicity of Plasmodium yoelii merozoite surface protein 4\/5 produced in transgenic plants","volume":"38","author":"Wang","year":"2008","journal-title":"Int. J. Parasitol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Chitnis, C.E., Mukherjee, P., Mehta, S., Yazdani, S.S., Dhawan, S., Shakri, A.R., Bhardwaj, R., Gupta, P.K., Hans, D., and Mazumdar, S. (2015). Phase I clinical trial of a recombinant blood stage vaccine candidate for Plasmodium falciparum malaria based on MSP1 and EBA175. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137816"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Boes, A., Spiegel, H., Voepel, N., Edgue, G., Beiss, V., Kapelski, S., Fendel, R., Scheuermayer, M., Pradel, G., and Bolscher, J.M. (2015). Analysis of a multi-component multi-stage malaria vaccine candidate\u2014Tackling the cocktail challenge. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131456"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pt.2007.12.002","article-title":"Apical membrane antigen 1: A malaria vaccine candidate in review","volume":"24","author":"Remarque","year":"2008","journal-title":"Trends Parasitol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1042\/BCJ20180017","article-title":"Protein\u2013protein interaction studies reveal the Plasmodium falciparum merozoite surface protein-1 region involved in a complex formation that binds to human erythrocytes","volume":"475","author":"Paul","year":"2018","journal-title":"Biochem. J."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/iai.61.6.2462-2467.1993","article-title":"A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice","volume":"61","author":"Daly","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1128\/iai.64.8.3310-3317.1996","article-title":"Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes","volume":"64","author":"Crewther","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.159.7.3400","article-title":"Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: Correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells","volume":"159","author":"Hirunpetcharat","year":"1997","journal-title":"J. Immunol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria vaccines: Recent advances and new horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12033-020-00271-x","article-title":"An AMA1\/MSP119 Adjuvanted Malaria Transplastomic Plant-Based Vaccine Induces Immune Responses in Test Animals","volume":"62","author":"Radwan","year":"2020","journal-title":"Mol. Biotechnol."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Kim, H., Kwon, K.W., Park, J., Kang, H., Lee, Y., Sohn, E.-J., Hwang, I., Eum, S.-Y., and Shin, S.J. (2020). Plant-Produced N-glycosylated Ag85A Exhibits Enhanced Vaccine Efficacy Against Mycobacterium tuberculosis HN878 Through Balanced Multifunctional Th1 T Cell Immunity. Vaccines, 8.","DOI":"10.3390\/vaccines8020189"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/bab.1867","article-title":"Expression of ESAT-6 antigen from Mycobacterium tuberculosis in broccoli: An edible plant","volume":"67","author":"Saba","year":"2020","journal-title":"Biotech. Appl. Biochem."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2019.08.016","article-title":"Chloroplast-based inducible expression of ESAT-6 antigen for development of a plant-based vaccine against tuberculosis","volume":"305","author":"Sabaa","year":"2019","journal-title":"J. Biotechnol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"581100","DOI":"10.3389\/fpls.2020.581100","article-title":"Efficient Plant Production of Recombinant NS1 Protein for Diagnosis of Dengue","volume":"11","author":"Xisto","year":"2020","journal-title":"Front. Plant Sci."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Ponndorf1, D., Meshcheriakova, Y., Thuenemann, E.C., Alonso, A.D., Overman, R., Holton, N., Dowall, S., Kennedy, E., Stocks, M., and Lomonossoff, G.P. (2021). Plant-made dengue virus-like particles produced by coexpression of structural and non-structural proteins induce a humoral immune response in mice. Plant Biotech. J., 19, 745\u2013756.","DOI":"10.1111\/pbi.13501"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"912","DOI":"10.12688\/f1000research.8010.1","article-title":"The potential of plants as a system for the development and production of human biologics","volume":"5","author":"Chen","year":"2016","journal-title":"F1000Research"},{"key":"ref_252","first-page":"256135","article-title":"Manufacturing economics of plant made biologics: Case studies in therapeutic and industrial enzymes","volume":"2014","author":"Tu","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12010-014-1320-5","article-title":"Techno-economic analysis of horseradish peroxidase production using a transient expression system in Nicotiana benthamiana","volume":"175","author":"Walwyn","year":"2015","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/bit.27093","article-title":"A simplified techno-economic model for the molecular pharming of antibodies","volume":"116","author":"Twyman","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/pbi.12127","article-title":"Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies","volume":"11","author":"Ma","year":"2013","journal-title":"Plant Biotechnol. J."},{"key":"ref_256","first-page":"81","article-title":"Advanced plant-based glycan engineering","volume":"9","author":"Steinkellner","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/glycob\/cwy092","article-title":"Glycoengineered antibodies: Towards the next-generation of immunotherapeutics","volume":"29","author":"Mastrangeli","year":"2019","journal-title":"Glycobiology"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/bit.26503","article-title":"N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions","volume":"115","author":"Marusic","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"15923","DOI":"10.1074\/jbc.M109.088401","article-title":"In planta protein sialylation through overexpression of the respective mammalian pathway","volume":"285","author":"Castilho","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"36518","DOI":"10.1074\/jbc.M112.402685","article-title":"Engineering of sialylated mucin-type O-glycosylation in plants","volume":"287","author":"Castilho","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMoa1409838","article-title":"Clinical care of two patients with Ebola virus disease in the United States","volume":"371","author":"Lyon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ijms19010054","article-title":"Development of antibody therapeutics against flaviviruses","volume":"19","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1099\/jgv.0.000635","article-title":"Plant produced anti-dengue virus monoclonal antibodies exhibit reduced antibody dependent enhancement of infection activity","volume":"97","author":"Dent","year":"2016","journal-title":"J. Gen. Virol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pbi.13194","article-title":"In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered Nicotiana benthamiana plants","volume":"18","author":"Hurtado","year":"2019","journal-title":"Plant Biotechnol. J."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/bit.22299","article-title":"A DNA replicon system for rapid high-level production of virus-like particles in plants","volume":"103","author":"Huang","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/bit.22652","article-title":"High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system","volume":"106","author":"Huang","year":"2010","journal-title":"Biotechnol. Bioeng."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pep.2018.06.011","article-title":"High-level expression and enrichment of norovirus virus-like particles in plants using modified geminiviral vectors","volume":"151","author":"Diamos","year":"2018","journal-title":"Protein Exp. Purif."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"e6600","DOI":"10.7717\/peerj.6600","article-title":"Evaluation of a toxoid fusion protein vaccine produced in plants to protect poultry against necrotic enteritis","volume":"7","author":"Hunter","year":"2019","journal-title":"PeerJ"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/pbi.12931","article-title":"Chimeric 3\u2032 flanking regions strongly enhance gene expression in plants","volume":"16","author":"Diamos","year":"2018","journal-title":"Plant Biotechnol. J."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/infdis\/jiu085","article-title":"Engineering, expression in transgenic plants and characterisation of e559, a rabies virus-neutralising monoclonal antibody","volume":"210","author":"Teh","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_275","unstructured":"Wilson, J., and Dellorto, D. (2014). 9 Questions about This New Ebola Drug, CNN."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1467-7652.2007.00306.x","article-title":"Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans","volume":"6","author":"Rademacher","year":"2008","journal-title":"Plant Biotechnol. J."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1073\/pnas.0708841104","article-title":"Cost-effective production of a vaginal protein microbicide to prevent HIV transmission","volume":"105","author":"Ramessar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/pbi.12360","article-title":"Rice endosperm produces an underglycosylated and potent form of the HIV-neutralizing monoclonal antibody 2G12","volume":"14","author":"Vamvaka","year":"2016","journal-title":"Plant Biotechnol. J."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1038\/s41598-020-63052-1","article-title":"Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications","volume":"10","author":"Singh","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.copbio.2015.12.007","article-title":"Molecular pharming\u2014VLPs made in plants","volume":"37","author":"Marsian","year":"2016","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","article-title":"The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and saferesponse to pandemic influenza","volume":"8","author":"Couture","year":"2010","journal-title":"Plant Biotechnol. J."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"g5488","DOI":"10.1136\/bmj.g5488","article-title":"US signs contract with ZMapp maker to accelerate development of the Ebola drug","volume":"349","author":"McCarthy","year":"2014","journal-title":"BMJ"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00425-017-2689-5","article-title":"Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants","volume":"246","author":"Angulo","year":"2017","journal-title":"Planta"},{"key":"ref_285","first-page":"252","article-title":"A perspective on the development of plant-made vaccines in the fight against ebola virus","volume":"8","author":"Angulo","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"20695","DOI":"10.1073\/pnas.1117715108","article-title":"A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge","volume":"108","author":"Phoolcharoen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11103-018-0744-7","article-title":"High-level expression of the HIV entry inhibitor griffithsin from the plastid genome and retention of biological activity in dried tobacco leaves","volume":"97","author":"Hoelscher","year":"2018","journal-title":"Plant Mol. Biol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1007\/s00253-019-10038-3","article-title":"Production of HIV-1-based virus-like particles for vaccination: Achievements and limits","volume":"103","author":"Cervera","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00299-011-1194-8","article-title":"Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV)","volume":"31","year":"2012","journal-title":"Plant Cell Rep."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.biotechadv.2012.06.002","article-title":"Plant made anti-HIV microbicides\u2013a field of opportunity","volume":"30","author":"Rybicki","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1080\/21645515.2017.1356497","article-title":"Plant-made vaccines and reagents for the one health initiative","volume":"13","author":"Rybicki","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/pbi.12796","article-title":"Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice","volume":"16","author":"Yang","year":"2018","journal-title":"Plant Biotechnol. J."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2018.02.073","article-title":"A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity","volume":"36","author":"Lai","year":"2018","journal-title":"Vaccine"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2019.1704264","article-title":"The role of plant expression platforms in biopharmaceutical development: Possibilities for the future","volume":"18","author":"Hefferon","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0264-410X(98)00388-0","article-title":"Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide","volume":"17","author":"McInerney","year":"1999","journal-title":"Vaccine"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-1759(98)00145-8","article-title":"Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization","volume":"220","author":"Durrani","year":"1998","journal-title":"J. Immunol. Meth."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.1128\/JVI.75.18.8434-8439.2001","article-title":"Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1","volume":"75","author":"Marusic","year":"2001","journal-title":"J. Virol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1016\/j.vaccine.2009.06.045","article-title":"Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice","volume":"27","author":"Lico","year":"2009","journal-title":"Vaccine"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jviromet.2010.01.017","article-title":"Immunogenic properties of chimeric potato virus X particles displaying the hepatitis C virus hypervariable region I peptide R9","volume":"166","author":"Schlosser","year":"2010","journal-title":"J. Virol. Meth."},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Cabral-Miranda, G., Heath, M.D., Mohsen, M.O., Gomes, A.C., Engeroff, P., Flaxman, A., Leoratti, F.M.S., El-Turabi, A., Reyes-Sandoval, A., and Skinner, M.A. (2017). Virus-like particle (VLP) plus microcrystalline tyrosine (MCT) adjuvants enhance vaccine efficacy improving T and B cell immunogenicity and protection against Plasmodium berghei\/vivax. Vaccines, 5.","DOI":"10.3390\/vaccines5020010"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.vaccine.2005.01.039","article-title":"Peptide-based candidate vaccine against respiratory syncytial virus","volume":"23","author":"Yusibov","year":"2005","journal-title":"Vaccine"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/0022-1317-78-6-1213","article-title":"Presentation of a foreign peptide on the surface of tomato bushy stunt virus","volume":"78","author":"Joelson","year":"1997","journal-title":"J. Gen. Virol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1016\/j.vaccine.2010.06.024","article-title":"Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes","volume":"28","author":"Hanafi","year":"2010","journal-title":"Vaccine"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"e1681","DOI":"10.1002\/wnan.1681","article-title":"Advancements in protein nanoparticle vaccine platforms to combat infectious disease","volume":"13","author":"Butkovich","year":"2021","journal-title":"WIREs Nanomed Nanobiotechnology"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3389\/fmicb.2017.02413","article-title":"Preclinical Development and Production of Virus-Like Particles as Vaccine Candidates for Hepatitis C","volume":"8","author":"Masavuli","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11248-005-5697-3","article-title":"Risk analysis for plant-made vaccines","volume":"14","author":"Kirk","year":"2005","journal-title":"Transgenic Res."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.biotechadv.2011.08.020","article-title":"Green factory: Plants as bioproduction platforms for recombinant proteins","volume":"30","author":"Xu","year":"2012","journal-title":"Biotechnol. Adv."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.4254\/wjh.v7.i22.2369","article-title":"Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus","volume":"7","author":"Tabll","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_309","doi-asserted-by":"crossref","unstructured":"Castilho, A., Bohorova, N., Grass, J., Bohorov, O., Zeitlin, L., Whaley, K., Altmann, F., and Steinkellner, H. (2011). Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026040"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1387\/ijdb.130266ad","article-title":"Role of plant expression systems in antibody production for passive immunization","volume":"57","author":"Virdi","year":"2013","journal-title":"Int. J. Dev. Biol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/7\/761\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:27:38Z","timestamp":1760164058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/7\/761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":310,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["vaccines9070761"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9070761","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}